SOURCE: Techs Loanstar, Inc.

November 10, 2011 08:00 ET

Quture/TCLN Announces Dr. Reid Jilek as Chairman of Its Scientific and Business Advisory Board

WEST PALM BEACH, FL--(Marketwire - Nov 10, 2011) - Techs Loanstar, Inc. (OTCQB: TCLN) (PINKSHEETS: TCLN) and Quture, Inc. ("Quture") today announced that the company retained Dr. Reid Jilek as Chairman of its Scientific and Business Advisory Board.

Dr. Jilek holds advanced degrees in both life science and engineering disciplines. In addition, he served as a Presidential Fellow and a White House Fellow Candidate. He has published over 40 papers in national and international peer-reviewed scientific journals. After completing his National Library of Medicine Post-Doctoral by developing computer and mathematical models for malaria, Dr. Jilek decided to utilize his medical and scientific acumen in a business development capacity by acting as a VP of Business Development for private and public companies as well as a research institute.

"The announcement of Dr. Reid Jilek as the Chairman of our Advisory Boards is an enormous accomplishment for Quture, an honor distinguishing the Company internationally and an extraordinary milestone," said Landon Feazell, Quture/TCLN's Chairman and CEO. "Dr. Jilek brings the rare combination of scientific, engineering, and business expertise and extensive real-world experience to our enterprise. His involvement has already made significant impacts which will be announced in the days and weeks ahead from his extensive and diverse relationships for our business and strategic successes."

Dr. Jilek has developed more than 8,000 professional contacts worldwide within the healthcare industry and investment world including key figures with the following fields: therapeutics, diagnostics, vaccines, gene therapy, medical devices, preclinical and clinical contract research organizations, nutraceuticals, generics, telemedicine, botanical, and biotech products, as well as the venture capital and investment banking industries.

Dr. Jilek was a founding member of Frederick Research Center and of Asia Pacific Alliance Company. He has served on the Board of Directors, Scientific or Medical Advisory Boards, or Advisory Boards for more than 40 private and public companies since 1990 within the US, Canada, Mexico, Japan, Taiwan, China, Portugal, Russia, Israel and Germany. He has also served as the CEO of three companies.

Mr. Feazell went on to add, "Dr. Jilek's leadership of our Advisory Boards will mature our plans not only for the Advisory Board but for appointment of a distinguished and accomplished, independent Board of Directors. That same leadership will leverage his vast expertise and experience in international markets with a truly global strategy, presence, and achievement of becoming the international standard of performance measurement."

A copy of the complete SEC 8-K filing can be viewed here:

About Quture, Inc.

Quture, Inc., a Nevada corporation, is positioned to rapidly become the international standard in healthcare performance and outcomes measurement and analytics to accomplish its corporate mission. Quture provides healthcare organizations, insurers, government payers, and other stakeholders in the healthcare community with performance measurement tools and data sets. Industry experts agree that performance and outcomes measurement is the "transformative tool" to reduce medical cost and improve quality of care. Quture's management team has 35 years of experience and a long history of working with many of the nation's leading healthcare institutions as a leader and innovator in measuring clinical performance. Quture is now testing its revolutionary solution to effectively and efficiently measure clinical performance from multiple vendor databases.

Forward-Looking Statements

This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law.

Contact Information

  • For Further Information:

    Constellation Asset Advisors, Inc.
    Jens Dalsgaard
    +1 (415) 524-8500

    For Media and Public Relations:
    Propheta Communications, Inc.
    Kevin Mercuri